Compare Cytokinetics Inc (CYTK) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Hyatt Hotels Corporation — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Hyatt Hotels Corporation trades at $159.3 (market cap $15.02B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Hyatt Hotels Corporation for 148 Days on average.
| CYTK | H | |
|---|---|---|
Market Cap | $8.62B | $15.02B |
Volume | 2,594,626 | 842,340 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $202.09 |
52-Week Low | $54.76 | $135.42 |
Typical Hold Time | 19 Days | 148 Days |
Enterprise Value | $8.72B | $18.93B |
Dividend Yield | — | 0.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Hyatt Hotels (H) trades at $157.14, down 1.24% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows mixed fundamentals: revenue grew to $7.10B in 2025, but net income was a loss of $52M, and valuation ratios like a P/E of 194 appear elevated. Recent news highlights expansion efforts, including a loyalty collaboration with Delta Air Lines and new hotel openings, signaling growth initiatives amid operational challenges.
The outlook for H is cautious; analyst consensus is a Moderate Buy with a $197.77 price target, but high debt levels and volatile profitability pose risks. Upside depends on sustained revenue growth and margin improvement, while downside risks include economic sensitivity and execution delays in new projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
